• 14083 Citations
  • 50 Scopus h-Index
1978 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1995 2019

2019
1 Citation (Scopus)

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Jan 1 2019, In : Oncology (Switzerland).

Research output: Contribution to journalArticle

Open Access
gemcitabine
Factor VIIa
Pancreatic Neoplasms
Disease-Free Survival
Survival

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Gracian, A. C., Mangel, L., Fernandez, E. E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 1 2019, In : British journal of cancer.

Research output: Contribution to journalComment/debate

Open Access
Colorectal Neoplasms
Placebos
Neoplasms
veliparib
6 Citations (Scopus)

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., Ahn, D., Bekaii-Saab, T. & Borad, M. J., Jan 1 2019, In : JAMA Oncology.

Research output: Contribution to journalArticle

gemcitabine
Biliary Tract Neoplasms
Nanoparticles
Cisplatin
Clinical Trials
13 Citations (Scopus)

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L., Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin, D., Shaked, A., Gao, M. & 9 others, Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E. L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L., Mar 14 2019, In : Nature. 567, 7747, p. 249-252 4 p.

Research output: Contribution to journalLetter

Hepatocytes
Liver
STAT3 Transcription Factor
Neoplasm Metastasis
Circulating Neoplastic Cells
5 Citations (Scopus)

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., Mehan, P. T., Gaur, R., Seery, T., Guthrie, K. A. & Hochster, H. S., May 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 13, p. 1062-1069 8 p.

Research output: Contribution to journalArticle

Hyaluronoglucosaminidase
Adenocarcinoma
Hyaluronic Acid
Survival
irinotecan
2018
3 Citations (Scopus)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J., Kang, Y. K., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., Xiong, H., Komarnitsky, P., Shepherd, S. P., Hurwitz, H. & Lenz, H. J., Mar 12 2018, (Accepted/In press) In : British Journal of Cancer. p. 1-9 9 p.

Research output: Contribution to journalArticle

irinotecan
Neoplasms
Fluorouracil
Maximum Tolerated Dose
Leucovorin
1 Citation (Scopus)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 1 2018, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Placebos
Neutropenia
Disease-Free Survival
veliparib
2 Citations (Scopus)
Immune System
Adenocarcinoma
Neoplasms
Therapeutics
Aptitude
3 Citations (Scopus)

First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors

Strickler, J. H., Weekes, C. D., Nemunaitis, J., Ramanathan, R. K., Heist, R. S., Morgensztern, D., Angevin, E., Bauer, T. M., Yue, H., Motwani, M., Parikh, A., Reilly, E. B., Afar, D., Naumovski, L. & Kelly, K., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3298-3306 9 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Neoplasms
Maximum Tolerated Dose
Safety
Fatigue
17 Citations (Scopus)

Metastatic pancreatic cancer: ASCO clinical practice guideline update

Sohal, D. P. S., Kennedy, E. B., Khorana, A., Copur, M. S., Crane, C. H., Garrido-Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., Ramanathan, R. K., Ruggiero, J. T., Shah, M. A., Urba, S., Uronis, H. E., Lau, M. W. & Laheru, D., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2545-2556 12 p.

Research output: Contribution to journalReview article

irinotecan
Pancreatic Neoplasms
Practice Guidelines
gemcitabine
Fluorouracil

Novel immunotherapy strategies for hepatobiliary cancers

Deleon, T. T., Zhou, Y., Nagalo, B., Yokoda, R. T., Ahn, D., Ramanathan, R. K., Salomao, M. A., Aqel, B. A., Mahipal, A., Bekaii-Saab, T. & Borad, M. J., Sep 1 2018, In : Immunotherapy. 10, 12, p. 1077-1091 15 p.

Research output: Contribution to journalReview article

Immunotherapy
Neoplasms
Oncolytic Virotherapy
Therapeutics
T-Cell Antigen Receptor
8 Citations (Scopus)

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

Deleon, T. T., Ahn, D., Bogenberger, J. M., Anastasiadis, P. Z., Arora, M., Ramanathan, R. K., Aqel, B. A., Vasmatzis, G., Truty, M., Oklu, R., Bekaii-Saab, T. & Borad, M. J., Mar 1 2018, In : Future Oncology. 14, 6, p. 553-566 14 p.

Research output: Contribution to journalReview article

Biliary Tract Neoplasms
Hepatocellular Carcinoma
Neoplasms
Biomarkers
Therapeutics
14 Citations (Scopus)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Infante, J. R., Korn, R. L., Rosen, L. S., Lorusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In : British Journal of Cancer. 118, 2, p. 153-161 9 p.

Research output: Contribution to journalArticle

Hyaluronoglucosaminidase
Neoplasms
Hyaluronic Acid
Maximum Tolerated Dose
Myalgia
65 Citations (Scopus)

Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma

Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., El-Khoueiry, A., Kelley, R. K., Borbath, I., Choo, S. P., Oh, D. Y., Philip, P. A., Chen, L. T., Reungwetwattana, T., Van Cutsem, E., Yeh, K. H. & 9 others, Ciombor, K., Finn, R. S., Patel, A., Sen, S., Porter, D., Isaacs, R., Zhu, A. X., Abou-Alfa, G. K. & Bekaii-Saab, T., Jan 20 2018, In : Journal of Clinical Oncology. 36, 3, p. 276-282 7 p.

Research output: Contribution to journalArticle

Receptor, Fibroblast Growth Factor, Type 2
Cholangiocarcinoma
Hyperphosphatemia
Stomatitis
gemcitabine
4 Citations (Scopus)

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 1 2018, In : Molecular Cancer Therapeutics. 17, 1, p. 215-221 7 p.

Research output: Contribution to journalArticle

Antibodies, Monoclonal, Humanized
Pharmacokinetics
Neoplasms
Liver
Enzymes
2017
3 Citations (Scopus)

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Korn, R. L., Von Hoff, D. D., Borad, M. J., Renschler, M. F., McGovern, D., Curtis Bay, R. & Ramanathan, R. K., Aug 3 2017, In : Cancer Imaging. 17, 1, 23.

Research output: Contribution to journalArticle

gemcitabine
Fluorodeoxyglucose F18
Pancreatic Neoplasms
Positron-Emission Tomography
Survival

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D. & Barrett, M., Dec 1 2017, In : Journal of Gastrointestinal Oncology. 8, 6, p. 925-935 11 p.

Research output: Contribution to journalArticle

Pancreatic Neoplasms
Immunohistochemistry
Neoplasms
Biopsy
irinotecan
9 Citations (Scopus)

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

Barrett, M., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K. & Von Hoff, D. D., Aug 8 2017, In : British Journal of Cancer. 117, 4, p. 572-582 11 p.

Research output: Contribution to journalArticle

Adenocarcinoma
Genome
Neoplasms
DNA Repair-Deficiency Disorders
Clinical Trials
34 Citations (Scopus)

Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study

Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., Cain, J., Hendriks, B. S., Drummond, D. C., Bayever, E. & Fitzgerald, J. B., Jul 15 2017, In : Clinical Cancer Research. 23, 14, p. 3638-3648 11 p.

Research output: Contribution to journalArticle

irinotecan
Ferrosoferric Oxide
Neoplasms

Development of new pharmaceutical therapies for pancreatic adenocarcinoma

Ramanathan, R. K., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 7-10 4 p.

Research output: Contribution to journalArticle

Adenocarcinoma
Pharmaceutical Preparations
Therapeutics
21 Citations (Scopus)

Immunotherapy in pancreatic cancer treatment: A new frontier

Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J., Jan 1 2017, In : Therapeutic Advances in Gastroenterology. 10, 1, p. 168-194 27 p.

Research output: Contribution to journalReview article

Pancreatic Neoplasms
Immunotherapy
Tumor Microenvironment
Therapeutics
Immune Tolerance
106 Citations (Scopus)

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A., 2017, In : Cancer Discovery. 7, 6, p. 620-629 10 p.

Research output: Contribution to journalArticle

Mutation
Neoplasms
Small Cell Lung Carcinoma
Antineoplastic Agents
Ovarian Neoplasms
4 Citations (Scopus)

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Weiss, G. J., Jameson, G., von Hoff, D. D., Valsasina, B., Davite, C., Di Giulio, C., Fiorentini, F., Alzani, R., Carpinelli, P., Di Sanzo, A., Galvani, A., Isacchi, A. & Ramanathan, R. K., Jul 20 2017, (Accepted/In press) In : Investigational New Drugs. p. 1-11 11 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Neoplasms
Oral Administration
Safety
Therapeutics
47 Citations (Scopus)

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., Jin, H., Parmar, H., Hsu, J. Y., Von Hoff, D. D. & Baselga, J., Jul 1 2017, In : Cancer Discovery. 7, 7, p. 704-715 12 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Neoplasms
Growth Inhibitors
Stomatitis
Mutation
13 Citations (Scopus)

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis

Borazanci, E., Millis, S. Z., Kimbrough, J., Doll, N., von Hoff, D. & Ramanathan, R. K., 2017, In : Journal of Gastrointestinal Oncology. 8, 1, p. 164-172 9 p.

Research output: Contribution to journalArticle

Appendiceal Neoplasms
Fluorescence In Situ Hybridization
Immunohistochemistry
irinotecan
Goblet Cells
Adenocarcinoma

Recent advances in the treatment of pancreatic adenocarcinoma

Braiteh, F., Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 1-2 2 p.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
irinotecan
oxaliplatin
9 Citations (Scopus)

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Sonbol, M. B., Firwana, B., Wang, Z., Almader-Douglas, D., Borad, M. J., Makhoul, I., Ramanathan, R. K., Ahn, D. & Bekaii-Saab, T., Dec 1 2017, In : Cancer. 123, 23, p. 4680-4686 7 p.

Research output: Contribution to journalArticle

oxaliplatin
irinotecan
Meta-Analysis
Adenocarcinoma
Disease-Free Survival
1 Citation (Scopus)

Targeting the stroma in pancreatic cancer

Ahn, D. & Ramanathan, R. K., Dec 1 2017, In : Chinese Clinical Oncology. 6, 6, 65.

Research output: Contribution to journalReview article

Pancreatic Neoplasms
Tumor Microenvironment
Therapeutic Uses
Immunosuppression
Neoplasms
10 Citations (Scopus)

Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study

Kunzmann, V., Ramanathan, R. K., Goldstein, D., Liu, H., Ferrara, S., Lu, B., Renschler, M. F. & Von Hoff, D. D., 2017, In : Pancreas. 46, 2, p. 203-208 6 p.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Tumor Burden
Neoplasms
Adenocarcinoma

Virotherapies in pancreatic cancer

Ahn, D. & Ramanathan, R. K., Sep 27 2017, Current and Emerging Therapies in Pancreatic Cancer. Springer International Publishing, p. 309-322 14 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pancreatic Neoplasms
2016
1 Citation (Scopus)
Vascular Endothelial Growth Factor Receptor-2
Stomach Neoplasms
Stroke
Thromboembolism
Brain Ischemia
34 Citations (Scopus)

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B. & Ko, A., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 654-660 7 p., mdw006.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Survival
130-nm albumin-bound paclitaxel
24 Citations (Scopus)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study

Kasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A. F. & Yoshino, T., Jul 13 2016, In : BMC Cancer. 16, 1, 467.

Research output: Contribution to journalArticle

Neutropenia
Colorectal Neoplasms
Cohort Studies
Drug Therapy
Survival
10 Citations (Scopus)

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers

Borad, M. J., Egan, J. B., Condjella, R. M., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Halfdanarson, T. R., Mc Williams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., Aldrich, J. & 17 others, Kurdoglu, A., Izatt, T., Christoforides, A., Cherni, I., Nasser, S., Reiman, R., Cuyugan, L., McDonald, J., Adkins, J., Mastrian, S. D., Valdez, R., Jaroszewski, D. E., Von Hoff, D. D., Craig, D. W., Stewart, A. K., Carpten, J. D. & Bryce, A. H., 2016, In : Scientific Reports. 6, 1, 25.

Research output: Contribution to journalArticle

Neoplasms
Therapeutics
DNA Fingerprinting
Patient Preference
Pharmaceutical Preparations
17 Citations (Scopus)

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

Goldstein, D., Von Hoff, D. D., Moore, M., Greeno, E., Tortora, G., Ramanathan, R. K., Macarulla, T., Liu, H., Pilot, R., Ferrara, S. & Lu, B., Jan 1 2016, In : European Journal of Cancer. 52, p. 85-91 7 p.

Research output: Contribution to journalArticle

gemcitabine
Peripheral Nervous System Diseases
Pancreas
Adenocarcinoma
Survival
19 Citations (Scopus)

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial

Scheithauer, W., Ramanathan, R. K., Moore, M., Macarulla, T., Goldstein, D., Hammel, P., Kunzmann, V., Liu, H., McGovern, D., Romano, A. & Von Hoff, D. D., Jun 1 2016, In : Journal of Gastrointestinal Oncology. 7, 3, p. 469-478 10 p.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Neutropenia
Thrombocytopenia
Fatigue
53 Citations (Scopus)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I. & 1 others, Ramanathan, R. K., Oct 1 2016, In : Annals of oncology : official journal of the European Society for Medical Oncology. 27, 10, p. 1928-1940 13 p.

Research output: Contribution to journalArticle

Class I Phosphatidylinositol 3-Kinases
Non-Hodgkin's Lymphoma
Maximum Tolerated Dose
Neoplasms
Follicular Lymphoma
3 Citations (Scopus)

Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review

Chang, J. M., Katariya, N. N., Lam-Himlin, D. M., Haakinson, D. J., Ramanathan, R. K., Halfdanarson, T. R., Borad, M. J., Pannala, R., Faigel, D. O., Moss, A. A. & Mathur, A., Oct 18 2016, (Accepted/In press) In : Case Reports in Gastroenterology. p. 605-612 8 p.

Research output: Contribution to journalArticle

Pancreas
Carcinoma
Acinar Cell Carcinoma
Neoplasms
Neuroendocrine Cells
111 Citations (Scopus)

Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline

Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O'Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., Ruggiero, J. T., Copur, M. S., Lau, M., Urba, S. & Laheru, D., Aug 10 2016, In : Journal of Clinical Oncology. 34, 23, p. 2784-2796 13 p.

Research output: Contribution to journalReview article

gemcitabine
irinotecan
Pancreatic Neoplasms
Practice Guidelines
Comorbidity
74 Citations (Scopus)

Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors

Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., Lorusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H. & Sachdev, J. C., Jul 1 2016, In : Clinical Cancer Research. 22, 13, p. 3157-3163 7 p.

Research output: Contribution to journalArticle

docetaxel
Nanoparticles
Appointments and Schedules
Pharmacokinetics
Neoplasms

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

Ramanathan, R. K., Korn, R. L., Chiorean, E. G., Liu, H. & Von Hoff, D. D., Aug 1 2016, In : Annals of Oncology. 27, 8, p. 1647-1648 2 p.

Research output: Contribution to journalLetter

Pancreatic Neoplasms
Positron-Emission Tomography
18 Citations (Scopus)

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J. L., Liu, H., McGovern, D., Lu, B. & Von Hoff, D. D., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 648-653 6 p., mdw020.

Research output: Contribution to journalArticle

gemcitabine
Positron-Emission Tomography
Pancreas
Adenocarcinoma
Electrons
23 Citations (Scopus)

Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors

Patnaik, A., Weiss, G. J., Leonard, J. E., Rasco, D., Sachdev, J. C., Fisher, T. L., Winter, L. A., Reilly, C., Parker, R. B., Mutz, D., Blaydorn, L., Tolcher, A. W., Zauderer, M. & Ramanathan, R. K., Feb 15 2016, In : Clinical Cancer Research. 22, 4, p. 827-836 10 p.

Research output: Contribution to journalArticle

Pharmacokinetics
Safety
Antibodies
Neoplasms
Cell Membrane
22 Citations (Scopus)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: A first-in-human, open-label, dose-escalation phase i study with expansion cohort

Burris, H. A., Bakewell, S., Bendell, J. C., Infante, J., Jones, S. F., Spigel, D. R., Weiss, G. J., Ramanathan, R. K., Ogden, A. & Von Hoff, D., Dec 1 2016, In : ESMO Open. 1, 6, e000154.

Research output: Contribution to journalArticle

Ruthenium Compounds
Safety
Maximum Tolerated Dose
Neoplasms
Pharmacokinetics
2015
5 Citations (Scopus)

90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Picozzi, V. J., Ramanathan, R. K., Lowery, M. A., Ocean, A. J., Mitchel, E. P., O'neil, B. H., Guarino, M. J., Conkling, P. R., Cohen, S. J., Bahary, N., Frank, R. C., Dragovich, T., Bridges, B. B., Braiteh, F. S., Starodub, A. N., Lee, F. C., Gribbin, T. E., Richards, D. A., Lee, M., Korn, R. L. & 11 others, Pandit-Taskar, N., Goldsmith, S. J., Intenzo, C. M., Sheikh, A., Manzone, T. C., Horne, H., Sharkey, R. M., Wegener, W. A., O'reilly, E. M., Goldenberg, D. M. & Von Hoff, D. D., Jun 7 2015, In : European Journal of Cancer. 51, 14, p. 1857-1864 8 p., 9522.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
Therapeutics
Radioimmunotherapy
3 Citations (Scopus)

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)

Infante, J. R., Ramanathan, R. K., George, D., Tan, E., Quinlan, M., Liu, A., Scott, J. W. & Sharma, S., 2015, In : Cancer Chemotherapy and Pharmacology. 75, 4, p. 729-737 9 p.

Research output: Contribution to journalArticle

Biological Availability
Tablets
Capsules
Meals
Fats
55 Citations (Scopus)

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

Barrett, M., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A., McCullough, A. E., Reddy, S. K., Ramanathan, R. K., Northfelt, D. W. & Pockaj, B. A., 2015, In : Oncotarget. 6, 28, p. 26483-26493 11 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Comparative Genomic Hybridization
Glioblastoma
Oligonucleotide Array Sequence Analysis
Disease-Free Survival
13 Citations (Scopus)

Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)

Dietsch, G. N., Randall, T. D., Gottardo, R., Northfelt, D. W., Ramanathan, R. K., Cohen, P. A., Manjarrez, K. L., Newkirk, M., Bryan, J. K. & Hershberg, R. M., Dec 15 2015, In : Clinical Cancer Research. 21, 24, p. 5445-5452 8 p.

Research output: Contribution to journalArticle

Toll-Like Receptor 8
Neoplasms
Healthy Volunteers
Pharmacokinetics
Biomarkers
2 Citations (Scopus)

Metastatic fibrolamellar hepatocellular carcinoma to the pancreas

Villa, N. A., Pannala, R., Faigel, D. O., Haakinson, D. J., Katariya, N., Ramanathan, R. K., Jaroszewski, D., Lidner, T. K. & Byrne, T., May 1 2015, In : Case Reports in Gastroenterology. 9, p. 266-271 6 p.

Research output: Contribution to journalArticle

Pancreas
Recurrence
Hepatocellular Carcinoma
Liver
Peritoneum